Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (6,803,716)	$ (14,850,591)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	514,269	546,913
Noncash interest expense	1,091,843	939,919
Stock compensation expense	241,619	189,670
Inducement expense related to warrant reprice		7,755,541
Change in fair value of derivative liabilities	(109,744)	101,390
Impairment of right-of-use asset		55,496
Changes in operating assets and liabilities
Accounts receivable	889,810	155,689
Inventory	(170,028)	(448,486)
Other assets	110,332	210,102
Accounts payable	(423,955)	(570,922)
Accrued compensation and other liabilities	(381,830)	949,351
Net cash used in operating activities	(5,041,400)	(4,965,928)
Cash flows from investing activities
Purchases of property and equipment	(38,713)	(850,885)
Net cash used in investing activities	(38,713)	(850,885)
Cash flows from financing activities
Proceeds from issuance of common stock warrants		255,751
Proceeds from issuance of common stock and pre-funded warrants in registered offering, net of selling costs		23,473,962
Proceeds from the exercise of common stock warrants, net of issuance costs		9,094,172
Payments on debt		(418,374)
Payments on finance lease obligations	(17,529)	(100,466)
Net cash (used in) provided by financing activities	(17,529)	32,305,045
Effects of exchange rates on cash	(413,093)	(628,998)
Net (decrease) increase in cash and cash equivalents and restricted cash	(5,510,735)	25,859,234
Cash and cash equivalents and restricted cash at beginning of period	36,632,186	14,107,255
Cash and cash equivalents and restricted cash at end of period	31,121,451	39,966,489
Supplemental disclosure of cash flow information
Cash paid for interest	1,120	26,029
Supplemental disclosures of noncash investing and financing activities
Right-of-use assets acquired through operating leases		$ 748,294